BROSSARD, QUEBEC, CANADA — (Marketwire) — 11/28/11 — DIAGNOS inc. (“DIAGNOS” or “the Corporation”) (TSX VENTURE: ADK), a leader in the use of artificial intelligence and advanced knowledge-extraction techniques, announces today the signing of an agreement with IRIS for the commercialization of CARA (Computer Assisted Retinal Analysis) in the USA and other countries. This signature comes after the FDA approval of our technology platform (press release dated July 19, 2011).
Intelligent Retina Imaging Systems (IRIS) has organised some of the top Retina Specialty groups around the world to deliver retina care to large populations of diabetic patients with local and regional oversight in partnership with DIAGNOS. “We believe that our IRIS model is an excellent solution in helping to prevent vision loss in the diabetic population. We have the ability to preserve the vision of most, if not all, diabetic patients if we can treat them at the appropriate time.” said Dr Sunil Gupta, President of IRIS.
Retina Specialty Institute is excited to be the first US-based IRIS client, and we are confident that this partnership will give us the tools required in the mass screening of high risk populations of diabetics, who often progress to advanced stages of retinopathy prior to diagnosis and treatment. Currently almost 70% of our patients are not being seen for their annual exam as recommended, and we are confident that our partnership with IRIS and DIAGNOS will have a positive affect in changing this.” said Dr Alan Franklin, MD, PhD, a partner in Retina Specialty Institute.
–We are pleased to be working in collaboration with Intelligent Retina Imaging Systems. We need representation in each state, and we understand the importance of having regional representation and oversight. With our IRIS partnership, we will now have access to local retina specialists that will provide services and optimal patient care throughout the Americas and the world. Understanding local culture and needs is essential to sustain long term success in the USA and around the world”, said Andre Larente, DIAGNOS- President.
About CARA
CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA-s image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras. CARA is a cost-effective tool for processing large numbers of images, in real-time.
About DIAGNOS
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including natural resources and healthcare.
For further information, please visit our website at or the SEDAR website at .
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.
Contacts:
Investor relations representative:
Andre Larente
President
DIAGNOS Inc.
(450) 678-8882
Louis Morin
Bid Capital Markets
(514) 845-1101
You must be logged in to post a comment Login